Literature DB >> 9601161

Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats.

A A Megens1, K Artois, J Vermeire, T Meert, F H Awouters.   

Abstract

Clinical studies report a low incidence of intestinal side effects with transdermally administered fentanyl (TTS-fentanyl) in comparison with oral morphine. To support these clinical data, analgesic and intestinal effects of both opioids were compared in rats. After subcutaneous injection, analgesia in the tail withdrawal reaction test was obtained at a peak effect dose of 0.032 mg/kg with fentanyl and 8.0 mg/kg with morphine. This analgesic dose exceeded the ED50 for inhibition of castor oil-induced diarrhea only slightly (1.1 x) in the case of fentanyl (0.028 mg/kg) but markedly (36 x) in the case of morphine (0.22 mg/kg). To reverse completely the antidiarrheal effect of equivalent analgesic doses of the opioids (their ED50S for analgesia lasting 2 hours), much more naloxone was required in the case of morphine (5.4 mg/kg) than in the case of fentanyl (0.19 mg/kg). After oral administration, the difference between both opioids was less pronounced. Analgesia was obtained at 0.85 mg/kg with fentanyl and 32 mg/kg with morphine. This analgesic dose only slightly (1.7 x) exceeded the antidiarrheal dose in the case of fentanyl (0.49 mg/kg) but significantly (6.2 x) in the case of morphine (5.2 mg/ kg). To reverse completely the antidiarrheal effect of equivalent analgesic oral doses of the opioids (their ED50S for analgesia lasting 2 hours), more naloxone was required in the case of morphine (11 mg/kg) than in the case of fentanyl (2.0 mg/kg). Rapid penetration of fentanyl into the brain is thought to be responsible for small dissociation between the analgesic and intestinal effect of this lipophilic opioid. The present data provide preclinical evidence to support the relatively low incidence of intestinal side effects observed clinically with the use of TTS-fentanyl in comparison with orally administered morphine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601161     DOI: 10.1016/s0885-3924(97)00371-0

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  16 in total

1.  [Strong opioids and constipation].

Authors:  A Schwarzer; F Nauck; E Klaschik
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

Review 2.  The role of opioids in cancer pain.

Authors:  Columba Quigley
Journal:  BMJ       Date:  2005-10-08

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Use of transdermal fentanyl in cancer patients with intestinal problems: four case studies.

Authors:  P Naughton; P Horan
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

5.  Successful use of transdermal fentanyl in patients with cancers of the prostate, ovary and stomach.

Authors:  K Patterson; S O'Donoghue
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 6.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 7.  Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer.

Authors:  Claudine M Chwieduk; Kate McKeage
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

Review 8.  Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.

Authors:  R B Muijsers; A J Wagstaff
Journal:  Drugs       Date:  2001       Impact factor: 9.546

9.  Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.

Authors:  Carla Ripamonti; Elena Fagnoni; Tiziana Campa; Cinzia Brunelli; Franco De Conno
Journal:  Support Care Cancer       Date:  2006-02-17       Impact factor: 3.603

10.  Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors.

Authors:  Rui Tao; Meghana Karnik; Zhiyuan Ma; Sidney B Auerbach
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.